Innate Pharma to host key opinion leader call on IPH4102 “TELLOMAK” clinical trial design and rationale


You May Also Like

TESARO Announces Participation in Two Investor Conferences

WALTHAM, Mass., Nov. 22, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical ...

Clementia Appoints Industry Executive Shawn Tomasello to its Board of Directors

Accomplished Biopharma Leader Brings Over 30 Years of Experience Leading Strategic and Commercial EffortsMONTREAL, ...